Krishna Institute Of Medical Sciences Limited · NSE:KIMS
Krishna Institute Of Medical Sciences — Q4 FY25 Earnings Presentation
33 slides from Krishna Institute Of Medical Sciences's earnings presentation, May 12, 2025
Slide 1: Letter to stock exchanges: Investor Presentation
12th May 2025 The General Manager, The Manager, Department of Corporate Services Listing Department Bombay Stock Exchange Ltd (BSE) National Stock Exchange of India Limited, Phiroze Jheejheebhoy Towers, Exchange Plaza, 5th Floor, Dalal Street, Plot No.C/1, 'G' Block, Mumbai - 400 001. Bandra - Kurla
Slide 2: Q4 FY25 Update
Q4 FY25 UPDATE Private & Confidential
Slide 3: Driven by a Vision
Driven by a Vision Affordable Quality Care VISION: Best-in-Class Facilities Patient Centric Systems & Processes S To be the most preferred NT healthcare services brand by TIE providing affordable care and best PA clinical outcomes to patients. Clinical Outcome Driven Excellence And to be the best pl
Slide 4: Multi Specialty Care
Multi Specialty Care Brain Eyes Bones and Spine Radiology • Neurology • Ophthalmology • Orthopedics • Imaging • Neurosurgery Gastro Intestinal Tract • Arthroscopic Surgery • Interventional Radiology • Psychiatry • Medical Gastroenterology • Spine Surgery Lab Services • Neuro Rehabilitation • Surgica
Slide 5: KIMS at a Glance
KIMS at a Glance Telangana Secunderabad (1000) Maharashtra Begumpet (290) Nagpur (334) Kondapur (200) + 500 beds under construction Nashik (325) Gachibowli (237) Thane (300) Asian Transcare (60) Sangli (350) MIPPL (10) Karnataka Andhra Pradesh Bengaluru Vizag (KIMS ICON: 434) Soulspace (450) - Under
Slide 6: Dr. B. Bhaskar Rao - Visionary Behind KIMS
Dr. B. Bhaskar Rao - Visionary Behind KIMS Chairman & Managing Director A legend in CT Surgery, Dr. Bollineni Bhaskar Rao {MBBS, MS, DNB (CT Surgery)} is one of the very few Cardio- Thoracic Surgeons in the country, who performed over 30000 surgeries in his career spanning over more than 25 years. W
Slide 7: Dr. Abhinay Bollineni
Dr. Abhinay Bollineni Chief Executive Officer Dr. Abhinay Bollineni joined KIMS Hospitals in 2013 and spent the next couple of years in Hospital Operations before taking charge of Strategy & Marketing for the Group in 2015. He was appointed as the CEO in 2019. Dr. B. Abhinay completed MBBS from the
Slide 8: Board of Directors
Board of Directors Dr. Bhaskara Rao Bollineni Dr. Abhinay Bollineni Mrs. Anitha Dandamudi Mr. Saumen Chakraborty Chairman & Managing Director Chief Executive Officer Whole-time Director Independent Director, Chairman (Audit Committee) Mr. Adwik Bollineni Mr. Venkata Ramudu Jasthi Mrs. Y. Prameela Ra
Slide 9: Shareholding Pattern - As on 31 March, 2025
Shareholding Pattern - As on 31 March, 2025 st Retail & Others, Retail Pre IPO, 4.6% 7.0% Promoter & Promoter Share Holder No of Shares Share Holding % Category Group, 38.8% Promoter 15,52,56,520 38.8% SBI MF 2,50,77,710 6.3% DII HDFC MF 1,90,41,819 4.8% DII FII, 17.2% AXIS MF 1,78,57,954 4.5% DII S
Slide 10: Modern Medical Technology
Modern Medical Technology 4-Arm HD da Vinci MrGFUS Focussed Other Key Equipments Robotic Surgical Ultrasound System Revolutionary Knifeless Brain • O-Arm Scanner Facilitates complex surgeries procedure for treating tremors. • Spy Glass that are virtually scarless. Proven to reduce Tremors • Fibrosca
Slide 11: South Asia's first and India's only centre to offer the TULSA-PRO
South Asia’s first and India’s only centre to offer the TULSA-PRO. Flawless Results in First TULSA-PRO Treatments • This cutting-edge, MRI-guided technology offers a minimally invasive treatment for conditions like Benign Prostatic Hyperplasia (BPH) and localized prostate cancer, delivering precise
Slide 12: South India's First Gamma Knife
South India’s FirstGamma Knife (Gold Standard In Brain Radiosurgery) Gamma Knife Introduced: Advancing Non-Invasive Brain Treatment • The Gamma Knife is now available, offering a non-invasive treatment option for selected brain conditions such as brain tumors, arteriovenous malformations (AVMs), tri
Slide 13: Many Firsts...
Many Firsts... • First in Asia in to do Trans catheter • India’s first COVID Double Lung • Number 1 in Nephrology treatments in Tricuspid Valve replacement transplant done in 2020 Andhra Pradesh* procedure done in 2018 • India’s first Breathing Lung transplant • Number 1 in Neurosurgery & Poly • Lar
Slide 14: Key Accomplishments
Key Accomplishments NAL ACCRED TIO IT NA AT ER ION INT QU Y ET LI AF A TY & PAT I E N T S Pharmacie De Qualite (PDQ) American Accreditation Commission Certification Overall PDQ Evaluation ‘Best Patient Friendly Hospital’ NABH Digital Standards Accreditation Ranked No. 1 Hospital International (AACI)
Slide 15: Consistent Performer over 2 decades
Consistent Performer over 2 decades (Rupees in Millions) 30,670 7,590 25,143 6,200 22,235 5,766 .7% : 2 9 26 .9% 16,711 GR G R : CA 5,217 CA 11,287 2,412 4,280 773 1,311 317 263 42 2005 2010 2015 2020 2022 2023** 2024 2025 2005 2010 2015 2020 2022*** 2023** 2024 2025 No. of No. of No. of No. of No.
Slide 16: Q4 FY25 Updates
Q4 FY25 Updates 15 Private & Confidential
Slide 17: Financial & Operational Highlights - 1/2
Financial & Operational Highlights - 1/2 (Rupees in Cr) FINANCIAL HIGHLIGHTS Q4 FY 25 Consolidated • Total revenue of INR 801 Cr, a growth of 25.7% on YoY and 1.4% on QoQ basis. • EBITDA of INR 203 Cr, a growth of 24.4% on YoY and a de growth of 1.2% on QoQ basis. • EBITDA margin at 25.3% vs. 25.5%
Slide 18: Financial & Operational Highlights - 2/2
Financial & Operational Highlights - 2/2 OPERATIONAL Q4 FY 25 Consolidated HIGHLIGHTS • ARPOB grew by 21.0% and 7.8% on YoY and QoQ basis respectively • ARPP grew by 8.4% and 3.4% on YoY and QoQ basis respectively FY25 Q4 Results Particulars Q4 FY25 Q3 FY25 Q4 FY24 QoQ YoY IP Volumes 53,918 54,013 4
Slide 19: Group Operating Performance - 1/2
Group Operating Performance - 1/2 IP VOLUME (‘000) OP VOLUME (‘000) 11.6% (0.2%) 14.1% (0.3%) 213 54 54 1,834 470 469 46 411 191 1,608 FY24 FY25 Q4 FY24 Q3 FY25 Q4 FY25 FY24 FY25 Q4 FY24 Q3 FY25 Q4 FY25 OCCUPANCY* ARPOB (‘000) 7.8% (11.3%) (2.7%) 22.7% 61.3% 58.4% 39.2 38.5 41.5 50.7% 31.9 48.0% 34.
Slide 20: Group Operating Performance - 2/2
Group Operating Performance - 2/2 Particulars FY24 FY25 Q4 FY24 Q3 FY25 Q4 FY25 Bed Capacity 3,975 5,179 3,975 4,859 5,179 Operational Beds 3,503 4,492 3,503 4,342 4,492 Census Beds 2,989 3,924 2,989 3,768 3,924 Non Census Beds 514 603 514 574 603 Occupied Beds 2,148 2,248 2,044 2,200 2,157 Occupanc
Slide 21: Group Financial Performance
Group Financial Performance (Rupees in Millions) TOTAL REVENUE** EBITDA** (1.2%) 1.4% 22.0% 24.7% 30,670 8,014 8,148 2,050 7,902 2,025 25,143 6,376 6,533 1,628 FY24 FY25 Q4 FY24 Q3 FY25 Q4 FY25 FY24 FY25 Q4 FY24 Q3 FY25 Q4 FY25 PBT* (0.4%) PAT* 21.5% 23.5% 14.7% 5,581 1,346 4,148 1061 925 4,595 1,34
Slide 22: Operational and Financial Performance - 1/2
Operational and Financial Performance - 1/2 Telangana Andhra Pradesh Particulars FY24 FY25 Q4 FY24 Q3 FY25 Q4 FY25 FY24 FY25 Q4FY24 Q3 FY25 Q4 FY25 Bed Capacity 1727 1797 1727 1797 1797 1914 2214 1914 2214 2214 Operational Beds 1612 1682 1612 1682 1682 1641 1806 1641 1841 1806 Census Beds 1324 1394
Slide 23: Operational and Financial Performance - 2/2
Operational and Financial Performance - 2/2 Maharashtra Kerala Group Particulars FY24 FY25 Q4 FY24 Q3 FY25 Q4 FY25 FY25 Q3 FY25 Q4 FY25 FY24 FY25 Q4 FY24 Q3 FY25 Q4 FY25 Bed Capacity 334 659 334 659 659 509 189 509 3975 5179 3975 4859 5179 Operational Beds 250 630 250 630 630 374 189 374 3503 4492 3
Slide 24: Speciality Mix
Speciality Mix Others Cardiac Sciences 23% 17% Renal Sciences 8% Mother & Child 10% Group FY25 Organ Oncology Transplant 6% 2% Gastric Sciences 9% Neuro Sciences 11% Orthopaedics 14% 23 Private & Confidential
Slide 25: Payor & Cluster Profile
Payor & Cluster Profile PAYOR MIX CLUSTER TOTAL REVENUE Maharashtra Kerala 2% 8% Aarogyasri Andhra Pradesh 6% 26% Cash Telangana Corporate Group 64% 12% 53% FY25 Group FY25 CLUSTER EBITDA Maharashtra Kerala (1%) Insurance 3% 29% Andhra Pradesh 24% Telangana Group 74% FY25 1) Telangana - Secunderabad
Slide 26: Key Achievements in Q4 FY25
Key Achievements in Q4 FY25 25 Private & Confidential
Slide 27: Key Achievements in Q4 FY25
Key Achievements in Q4 FY25 26 Private & Confidential
Slide 28: Key to our success
Key to our success Doctor Affordable Partnerships Quality Care Modern Medical Infra 27 Private & Confidential
Slide 29: Expansion plans
Expansion plans Current Incremental Approx. Revised Expected Units New Departments Beds Beds Capex Year of Operation Bangalore (Project-1) - 450 All Specialities 350-400 Cr Q2 FY26 Bangalore (Project-2) - 350 All Specialities 180-200 Cr Q2 FY26 Mumbai (Thane) - 300 All Specialities 500-525 Cr Q1 FY2
Slide 30: KIMS UAIMS Hospital, Sangli
KIMS UAIMS Hospital, Sangli About Sangli: Sangli is known as the sugar bowl of India due to its high sugarcane productivity. Sangli district is one of the most fertile and highly developed districts in Maharashtra. Sangli is very well accessible to 5 districts from Maharashtra i.e. Kolhapur, Satara,
Slide 31: Profit and Loss Statement
Profit and Loss Statement (Rupees in Millions) Consolidated Particulars Q4 FY25 Q3 FY25 Q4 FY24 QoQ(%) YoY(%) FY25 FY24 YoY(%) Operating Revenue 7,969 7,724 6,338 3.2% 25.7% 30,351 24,982 21.5% Other Income 45 178 38 -74.7% 18.4% 319 161 98.1% Total Revenue** 8,014 7,902 6,376 1.4% 25.7% 30,670 25,1
Slide 32: Corporate Structure (As on 31 March'25)
Corporate Structure (As on 31 March'25) st Krishna Institute of Medical Sciences Limited KIMS Secunderabad KIMS Nellore KIMS Rajahmundry KIMS Ongole KIMS Hospitals KIMS QNRI KIMS Swastha (100%) (100%) (100%) (100%) Bengaluru Visakhapatnam Kerala (100%) (100.0%) (100.0%) Doctor Partnership Hospitals
Slide 33: Thank You
Thank You 32 Private & Confidential
Krishna Institute of Medical Sciences — Q4 FY25 Earnings Presentation on 6ix